ClinicalTrials.gg
RecruitingNCT06966258Updated Dec 29, 2025

Inspire HER: Inspiring the Heart and Emotions for Radical Health

An interventional study of Inspire HER Intervention in Cardiovascular-kidney-metabolic Syndrome, Cardiovascular Diseases and Hypertension, sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Open to female participants aged 30 Years to 79 Years. Per ClinicalTrials.gov, last updated 2025-12-29.

Primary conditionHypertensionRegistry: Cardiovascular DiseasesReclassifiedWhy we changed it
Registry
Cardiovascular Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hypertension
Why
  1. The study's listed conditions name Hypertension, a narrower term within Cardiovascular Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
30 Years to 79 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Hypertension by University of Alabama at Birmingham — 13 open to participants now, 16 under way, 1 of them phase 3. Hypertension · University of Alabama at Birmingham.

Planned enrollment
17th of 38
90 · median 71
Started
2025
with 1 other
No phase
29 of 44
11 open now
Primary completion
2029-01
later than 7 of 15 live
Registered
36th of 44
by date

Among the 44 studies in Hypertension by University of Alabama at Birmingham, this one is the 17th largest by planned enrollment of the 38 interventional ones that give a count, is one of 2 that started in 2025, is one of 29 with no phase, reaches primary completion later than 7 of the 15 other live ones, and was the 36th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

13 of the 44 studies in Hypertension by University of Alabama at Birmingham are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 30 Years to 79 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Hypertension by University of Alabama at Birmingham, or all of them as a file.
02

Study summary

Poor heart health puts Black women at risk for a shorter life with more illness than people of any other non-indigenous racial group. We will refine and conduct a randomized, wait-list controlled trial of Inspire HER (a heart health lifestyle intervention for Black women that provides health education, physical activity, and social resources). We will also compare Inspire HER and Black Impact (a heart health intervention for Black men) data to study how women and men respond differently to stress. This trial aligns with American Heart Association's pledge to address heart health equity through new interventions that consider the person and the circumstances with which they live.

Read the detailed description

Poor heart health puts Black women at risk for a shorter life with more illness than people of any other non-indigenous racial group. Yet, few studies have focused on improving heart health in Black women. Our team built and studied a 24-week program called Black Impact for Black men with less than ideal heart health. Black Impact provides 45 minutes of exercise and 45 minutes of healthy diet education and connects Black men with a health coach, fitness trainer, and community health worker. In the first study of Black Impact, Black men (n=74) had improved heart health equal to a 19% lower risk of death from heart disease. These men also reported less stress, improvement in being able to control their health, and fewer unmet social needs. Now, a study of Black Impact in 340 Black men is ongoing to understand how Black Impact works with respect to stress and heart health. Black women have reported a need for a similar heart health program. Based on feedback from Black women (n=56), we adapted Black Impact for Black women (Inspire HER). Thus, we propose to refine the Inspire HER program for Black women. Then, we will do a clinical trial of Inspire HER compared to routine living (usual care) in Black women with elevated heart health risk. We will find out if the Inspire HER program reduces heart health risk more than usual care. We will also assess how the Inspire HER program "gets under the skin" to affect the body's response to stress. Lastly, we will compare the response to stress between women of Inspire HER and men of Black Impact. Importantly, we expect this study will show promising improvements in heart health and risk. This Inspire HER trial will lay the foundation for larger future studies. Inspire HER, comparing data from Black Impact, may also help us understand how women and men in heart health programs respond differently to stress. This trial aligns with American Heart Association's pledge to address heart health equity through new interventions that consider the person and the circumstances with which they live.

03

Conditions studied

  • Cardiovascular-kidney-metabolic Syndrome
  • Cardiovascular Diseases
  • Hypertension
  • Diabetes
  • Hyperlipidemia
  • Kidney Disease
  • Obesity
  • Smoking

Keywords

  • Cardiovascular Risk
  • Lifestyle intervention
04

In context

Hypertension Reclassified

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

This study's planned enrollment of 90 is close to the median of 100 across 4,585 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

University of Alabama at Birmingham is the lead sponsor of 1,422 studies on the registry; 277 are open to participants now.

Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.

Compared within Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cardiovascular Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
30 Years to 79 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Black women (self-report)
  • Adult ages 30-79 years
  • Stage 2 or greater Cardiovascular-Kidney-Metabolic Syndrome
  • English speaking
  • Lives in Metropolitan Birmingham, AL area.

Exclusion criteria

Exclusion Criteria:

- Healthcare provider-imposed physical activity limitations.

06

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Inspire HER Intervention

    Those in the Inspire Her intervention arm will receive the 24-week intervention.

    Behavioral: Inspire HER Intervention

  • No intervention
    Wait-list Control

    Those in the wait-list control arm will receive usual care.

Interventions

  • BehavioralInspire HER Intervention

    The Black Impact intervention is an academic-community-government partnership adapted from the Diabetes Prevention Program and American Heart Association Check, Change, Control programs based on stakeholder feedback and to afford incorporation of additional evidence-based strategies for influencing target outcomes. The intervention is a 24-week community-based lifestyle intervention to improve cardiovascular health among Black men. Each participant will be assigned to a group with \>5 participants based on participant proximity to a central community meeting location. Each team will be guided weekly by a health coach who delivers content and coaching around the lifestyle intervention modeled on the diabetes prevention program and check, change, control blood pressure program, a community health worker who helps to address social needs and connects participants to primary care services, and a trainer who leads physical activity. Teams meet for 90 minutes per week.

07

What researchers measure

Primary outcomes

  1. Feasibility (Preliminary Effect on PREVENT Score)

    The primary outcome for the randomized controlled trial is change in cardiovascular risk as defined by PREVENT Score (a 10-year risk estimator of cardiovascular events for individuals 30-79 years of age; measure utilizes sex, age, cholesterol blood pressure, body mass index, glomerular filtration rate, diabetes, smoking status, anti-hypertensive medication, lipid-lowering medication, urine creatinine, hemoglobin A1C, and social deprivation index). PREVENT score ranges from low (\<5%) to high (\>20%) risk with low risk being better. Linear mixed effects models with random intercepts will evaluate the change from baseline to 24 weeks in primary (PREVENT score). These models will assess differences between waitlist control and intervention participants using an interaction between time and treatment indicator. We will also evaluate qualitative exit (focus group) survey data to understand perceived effect.

    Time frame: 24 weeks

  2. Feasibility (Demand or Use of Intervention)

    Demand will be assessed by percent recruited of number contacted, participant self-rating of participation, percent using information at home. These data will be obtained from study records and exit survey (focus group) responses.

    Time frame: 24 weeks

  3. Feasibility (Acceptability or Participant Reaction to Intervention)

    Acceptability will be assessed by participant satisfaction with the intervention and participant attendance, perceptions of usefulness, and plans/real change of behavior to apply health promotion strategies. These data will be obtained by study records and exit (focus group) surveys.

    Time frame: 24 weeks

  4. Feasibility (Implementation or Intervention FIdelity)

    Implementation will be assessed using the Inspire HER curriculum and participant opinions of how the intervention was administered. These data will be obtained via study records and exit (focus group) surveys.

    Time frame: 24 weeks

  5. Feasibility (Practicality or Efficiency of Resource Allocation)

    Practicality will be assessed using intervention cost per participant and identifying any revenue/savings. These data will be obtained by evaluating grant budgetary documentation.

    Time frame: 24 weeks

Secondary outcomes

  1. Dose-Response on Preliminary Effect

    Dose-response will be assessed by studying the relationship between intervention engagement (i.e. attendance) and the primary study outcome (change in PREVENT score). These data will be obtained using study records and PREVENT score evaluation as identified in the primary outcome.

    Time frame: 24 weeks

  2. Change in Conserved Transcriptional Response to Adversity

    Evaluation of change in conserved transcriptional response to adversity (CTRA) will be measured via collection of blood and measuring leukocyte gene expression to determine the CTRA at baseline, 12 and 24 weeks. For the CTRA score, background subtraction and normalization of raw data, and operationalize inflammatory and antiviral gene activity will be performed. CTRA change will be calculated using between-subject differences using a linear mixed-effects to evaluate changes from baseline. The model will contain data from baseline (0 weeks), during-intervention (12 weeks), and post-intervention (24-weeks). These models will assess differences between waitlist control and intervention participants using an interaction between time and treatment indicator. Residual plots will examine model assumptions and model fit, with transformation of the outcomes used as needed to satisfy modelling assumptions and achieve appropriate model fit.

    Time frame: 24 weeks

  3. Change in 12,13-diHOME Expression and Associations with Biomarkers

    Evaluation of change in 12,13-diHOME expression will be measured via collection of blood and measuring leukocyte gene expression to determine the expression at baseline, 12 and 24 weeks. For the expression score, background subtraction and normalization of raw data, and operationalize inflammatory and antiviral gene activity will be performed. The expression change will be calculated using between-subject differences using a linear mixed-effects to evaluate changes from baseline. The model will contain data from baseline (0 weeks), during-intervention (12 weeks), and post-intervention (24-weeks). These models will assess differences between waitlist control and intervention participants using an interaction between time and treatment indicator. Residual plots will examine model assumptions and model fit, with transformation of the outcomes used as needed to satisfy modelling assumptions and achieve appropriate model fit.

    Time frame: 24 weeks

  4. Mechanistic transcriptomic stress and inflammatory response to Inspire HER in Black women as compared to Black men in Black Impact:

    Heterogeneity of treatment differences between women enrolled in the Inspire HER study and men enrolled in the Black Impact 2.0 study (NCT: NCT06055036) will be examined visually using lattice graphical displays. ComBat will evaluate and address potential batch effects in CTRA (as described in the secondary outcome above) data between the two studies. Linear mixed models will estimate potential heterogeneity in response by sex via inclusion of sex\*treatment interaction terms.

    Time frame: 24 weeks

08

Study locations

1 of 1 sites recruiting
09

References and documents

Publications

  • Joseph JJ, Nolan TS, Williams A, McKoy A, Zhao S, Aboagye-Mensah E, Kluwe B, Odei JB, Brock G, Lavender D, Gregory J, Gray DM 2nd. Improving cardiovascular health in black men through a 24-week community-based team lifestyle change intervention: The black impact pilot study. Am J Prev Cardiol. 2022 Jan 13;9:100315. doi: 10.1016/j.ajpc.2022.100315. eCollection 2022 Mar. PubMed 35146467 ↗

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: 3/31/2025; available without end date

Access criteria: Inspire HER will generate primary qualitative and quantitative data. Qualitative data will be derived from focus group interviews with participants and partners of the Inspire HER intervention. To facilitate data interpretation, documentation files (txt files) such as a data dictionary, interview and survey questionnaires, informed consent script and study protocol will be made publicly available via Dryad. Quantitative data will be derived from participants' survey responses about cardiometabolic and social health. We will produce data management and analytic files (CSV files) that will be posted on GitHub. Because of the sensitive nature of community-based research, policies and guidelines will require having a faculty member with expertise in health equity research, IRB approval, and a community partner to help interpret findings and create/enact a dissemination plan.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jan 2029, 38 months after the start.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 38 months is above that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2025
First posted
May 11, 2025
StartActual
Nov 15, 2025
Primary completionEst.
Jan 31, 2029
CompletionEst.
Mar 31, 2029
Last update
Dec 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06966258
Collaborators
American Heart Association, Ohio State University, Tuskegee University
Responsible party
Timiya Nolan (Associate Professor, University of Alabama at Birmingham) — Principal investigator
First posted
May 11, 2025
Start date
Nov 15, 2025
Primary completion
Jan 31, 2029 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Dec 29, 2025

Study contacts

LeAndrea D Anderson
Contact
leandreaanderson@uabmc.edu
205-996-0089
Timiya S Nolan, PhD
principal investigator · University to Alabama at Birmingha

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion